Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 28;13(12):e0209484.
doi: 10.1371/journal.pone.0209484. eCollection 2018.

Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men

Affiliations

Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men

Rupa R Patel et al. PLoS One. .

Abstract

Pre-exposure prophylaxis (PrEP) is effective in preventing HIV infections among men who have sex with men (MSM). PrEP uptake and adherence remain low and product preferences are unknown, especially among young African American MSM who are most at-risk. We conducted 26 qualitative interviews from 2014-2016 among young adult HIV-negative African American MSM regarding PrEP product preferences in Missouri. While the pill and injectable were most liked of all modalities, about a quarter preferred rectal products or patches. Most participants preferred a long-acting injectable (LAI) to daily oral pills due to better medication adherence and a dislike for taking pills. Many participants preferred daily oral pills to on-demand oral PrEP due to the inability to predict sex and the perception that insufficient time or medication would not achieve HIV protection with on-demand. A fear of needles and the perception that there would not be therapeutic levels for a long duration were concerns with injectable PrEP. Study findings highlight the need for a range of prevention options for African American MSM and can inform PrEP product development as well as dissemination and implementation efforts.

PubMed Disclaimer

Conflict of interest statement

RRP receives compensation for consulting from Gilead Sciences, Inc. and ViiV Healthcare. For the remaining authors, there are no conflicts of interest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

References

    1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2016; vol. 28 [cited 30 May 2018]. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
    1. Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238–43. 10.1016/j.annepidem.2017.02.003 - DOI - PMC - PubMed
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. 10.1056/NEJMoa1011205 - DOI - PMC - PubMed
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2015;387(10013):53–60. - PMC - PubMed
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. 10.1056/NEJMoa1108524 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances